The phase 3 ADVANCE OUTCOMES study of ralinepag met its primary endpoint and several important secondary endpoints, including increasing odds of clinical improvement by 47%, in predominantly ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Hosted on MSN
United Therapeutics Corporation (UTHR) Completes Phase 3 Enrollment for Promising PAH Drug Ralinepag
We recently published 10 Most Undervalued Pharma Stocks To Buy Now. United Therapeutics Corporation stands eighth among the most undervalued stocks. United Therapeutics Corporation (NASDAQ:UTHR) is ...
United Therapeutics is a Buy: strong core growth, a goal of $1B quarterly revenue by 2027, plus catalysts ralinepag & Tyvaso ...
Please provide your email address to receive an email when new articles are posted on . Patients took either ralinepag or placebo once daily for 28 weeks. The ralinepag group had a significantly lower ...
Treatment with ralinepag, an investigational prostacyclin receptor agonist, reduced the risk for clinical disease worsening by 55% compared to placebo in patients with pulmonary arterial hypertension ...
United Therapeutics plans to file for approval of ralinepag as a treatment for pulmonary arterial hypertension (PAH) before the end of the year, after positive results in a phase 3 trial. The drug ...
Dr. Martine Rothblatt framed the quarter around two Phase III programs, saying, "We just proved beyond a shadow of a doubt with a p-value of less than 0.0001 that we have 2 different therapeutics in 2 ...
United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically ...
The formulation is being developed in collaboration with United Therapeutics Corporation United Therapeutics made an additional $5 million payment to MannKind to support the rapid advancement of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results